Dishman Carbogen Amcis Ltd

Dishman Carbogen Amcis Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (INR)124.75
  • Today's Change-5.05 / -3.89%
  • Shares traded608.88k
  • 1 Year change-32.57%
  • Beta1.8077
Data delayed at least 15 minutes, as of Mar 31 2023 11:16 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dishman Carbogen Amcis Limited is engaged in contract research and manufacturing services (CRAMS) and the manufacture and supply of marketable molecules, such as specialty chemicals, vitamins and chemicals, and disinfectants. The Company's segments include CRAMS and Vitamin - D, Bulk Drugs, Quats, Specialty Chemicals and traded goods. The Company assists pharma companies through various stages of drug development from process research and development to late-stage clinical and commercial manufacturing facilities, along with the supply of active pharmaceutical ingredients (APIs) and intermediates. The Company has manufacturing and research facilities in India, Switzerland, France, Netherlands, United Kingdom and China. The Company's subsidiaries include CARBOGEN AMCIS (Shanghai) Co. Ltd, Dishman Infrastructure Ltd., Dishman Carbogen Amcis (Singapore) Pte. Ltd., CARBOGEN AMCIS Holding AG and Dishman Biotech Ltd.

  • Revenue in INR (TTM)23.63bn
  • Net income in INR-36.60m
  • Incorporated2007
  • Employees1.17k
  • Location
    Dishman Carbogen Amcis LtdDishman Corporate HouseIscon-Bopal Road, AmbliAHMEDABAD 380058IndiaIND
  • Phone+91 2 717420102
  • Fax+91 7 926420198
  • Websitehttps://www.carbogen-amcis.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Morepen Laboratories Ltd14.22bn427.58m13.19bn2.38k30.84--18.680.92740.83670.836727.43--------5,980,358.00--8.25--17.0832.7233.953.015.86--24.75--0.0030.2021.044.7333.8946.89--
Novartis India Ltd4.01bn549.70m13.92bn81.0025.32--23.103.4722.2622.26162.31--------49,497,530.00--3.13--3.9748.8657.4213.717.18--31.51--75.564.86-9.43-117.80---29.150.00
TTK Health Care Ltd7.04bn284.73m14.67bn2.59k51.49--34.992.0820.16448.26498.06--------2,718,869.00--5.08--8.3751.2656.704.053.76--1.52--34.3125.882.57-49.68-0.24633.7214.87
Alembic Ltd1.08bn1.43bn15.16bn305.0010.57--17.4313.995.595.594.22--------3,552,853.00--3.40--3.5268.6650.2174.3558.12--53.28--6.086.39-11.87-35.238.8420.1255.18
Supriya Lifescience Ltd5.07bn978.40m15.35bn--15.68--14.063.0312.1612.1663.00------------------59.74--19.30----6.36----37.54--22.60------
Orchid Pharma Ltd6.34bn-174.88m15.64bn1.80k----25.082.47-4.27-4.74154.96-------------4.56---9.1342.0250.02-1.87-18.16---0.0711----24.33-7.0736.56--10.67--
Amrutanjan Health Care Ltd3.86bn418.46m16.81bn647.0040.27--35.804.3614.3014.30131.85--------5,964,019.00--18.30--22.8253.1154.9710.8413.46--118.34--21.8321.9313.329.8023.7943.8933.13
SeQuent Scientific Ltd14.38bn-189.19m18.04bn1.96k----52.871.25-0.768-0.76857.56--------7,343,974.00--4.11--6.4142.2243.83-1.385.11--0.1454--11.313.7615.44-57.09---16.24--
Gufic BioSciences Ltd6.80bn818.63m18.07bn1.38k22.07--18.102.668.458.4570.14--------4,918,800.00--12.07--26.7852.8244.4512.048.73--19.67--1.5459.7624.51116.6860.4284.5414.87
Dishman Carbogen Amcis Ltd23.63bn-36.60m19.56bn1.17k----6.860.8276-0.228-0.228151.42--------20,234,160.00--0.9727--1.1779.7074.41-0.15493.82--0.509--103.4111.964.55110.91-34.1525.67--
Shilpa Medicare Ltd11.27bn51.15m19.86bn2.73k379.01--20.101.760.60380.6038130.57--------4,127,259.00--5.79--7.1861.0159.950.593212.81--0.8471--7.6727.127.88-58.95-10.8323.1612.89
Unichem Laboratories Limited13.11bn-864.90m20.40bn3.17k----99.131.56-12.41-12.41185.65--------4,139,174.00---1.01---1.2163.7056.52-6.60-2.70---7.31----2.8112.69-3.68---3.255.92
Wockhardt Ltd26.28bn-6.10bn22.18bn2.96k------0.844-45.48-45.48189.17--------8,870,898.00---4.12---6.9658.9153.00-26.46-10.27---0.6223----19.26-4.2618.47---12.38--
Neuland Laboratories Ltd.10.40bn1.01bn23.15bn1.52k22.97--15.202.2378.5278.52810.59--------6,837,593.00--3.61--5.1246.6341.569.695.52--12.29--8.121.5110.11-20.856.3718.45--
Aarti Pharmalabs Ltd-100.00bn-100.00bn25.00bn----1.63----------169.74------------------------0.9527--0.1633------2,657,765.00------
Strides Pharma Science Ltd35.68bn-1.82bn25.86bn2.35k----47.150.7249-20.26-18.20396.69--------15,215,500.00---0.0665---0.107853.6549.14-5.27-0.1666--0.1015-----7.412.19-280.83---26.80--
Data as of Mar 31 2023. Currency figures normalised to Dishman Carbogen Amcis Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

6.81%Per cent of shares held by top holders
HolderShares% Held
HBM Partners AG (Investment Management)as of 31 Dec 20225.56m3.55%
HSBC Asset Management (India) Pvt Ltd.as of 28 Feb 20232.38m1.52%
ICICI Prudential Asset Management Co. Ltd.as of 28 Feb 20231.25m0.80%
Dimensional Fund Advisors LPas of 02 Mar 20231.19m0.76%
SSgA Funds Management, Inc.as of 02 Mar 2023202.07k0.13%
Dimensional Fund Advisors Ltd.as of 02 Mar 202351.87k0.03%
American Century Investment Management, Inc.as of 02 Mar 202337.73k0.02%
DFA Australia Ltd.as of 31 Jan 20234.15k0.00%
Motilal Oswal Asset Management Co. Ltd.as of 28 Feb 2023619.000.00%
Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 28 Feb 20230.000.00%
More ▼
Data from 31 Dec 2022 - 23 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.